Photo of Gabriela S. Hobbs,  MD

Gabriela S. Hobbs, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 724-1124
Fax: (617) 724-2525

Gabriela S. Hobbs, MD

Massachusetts General Hospital


  • Assistant Professor, Medicine, Harvard Medical School
  • Clinical Director, Leukemia, Massachusetts General Hospital


Research Abstract

My primary clinical and research focus is in advancing the care of patients with myeloproliferative neoplasms (MPN). My primary clinical objective is to continue to develop a panel of patients with MPN from local and regional referrals. The goal of my research is to design and implement clinical trials for patients with MPNs with a significant translational component through collaborations with laboratory investigators.

In August of 2014 I joined the Leukemia Service at Massachusetts General Hospital where I have established a MPN clinical and research program. From a clinical perspective, I routinely receive referrals from across the northeast and have a strong referral network; this has allowed me to develop a panel that consists primarily of MPN patients. From a research perspective, I lead the MPN clinical trials at MGH, all of which include a strong translational component based. The investigator-initiated studies for which I am the principal investigator include- A phase II, multicenter study, of ruxolitinib before, during and after transplant for patients with myelofibrosis (Protocol 17-569). A phase I study of Regorafenib for patients with advanced myeloid neoplasms (Protocol 16-464). A phase II, multicenter study utilizing ruxolitinib for maintenance after transplant for older patients with AML (Protocol 17-273). A phase II, multicenter study investigating the use of pembrolizumab for myelofibrosis (Protocol 17-480). In addition, I am the site PI for all pharmaceutical sponsored studies in MPN at MGH.

In addition to clinical trials work, I collaborate with Dr. Ann Mullally in translational research utilizing samples from the above-mentioned trials. This work includes defining the role of genetic mutations in predicting post- allogeneic hematopoietic stem cell transplantation (SCT) outcomes in myelofibrosis patients utilizing samples from protocol 17-569. In addition, we are investigating the role of immune dysregulation and immunotherapy in patients with MPN. This research utilizes samples of patients collected from my clinic as well as samples from a clinical trial utilizing the checkpoint inhibitor, Pembrolizumab in patients with Myelofibrosis.

Ultimately, my goal is to continue to grow a multidisciplinary MPN research program focused on providing high quality care to patients with MPNs, and to develop new treatment options for patients with MPN based on sound pre-clinical rationale, while strengthening collaborations with investigators across the Dana Farber Harvard Cancer Center and across the country.


Powered by Harvard Catalyst
  • How J, Hobbs G, Mullally A. Mutant calreticulin in myeloproliferative neoplasms. Blood 2019. PubMed
  • Slavin SD, Fenech A, Jankowski AL, Abel GA, Brunner AM, Steensma DP, Fathi AT, DeAngelo DJ, Wadleigh M, Hobbs GS, Amrein PC, Stone RM, Temel JS, El-Jawahri A. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer 2019. PubMed
  • Chen EC, Werner L, Hobbs GS, Narayan R, Amrein PC, Fathi AT, Brunner AM. Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leuk Lymphoma 2019. PubMed
  • Boiocchi L, Hasserjian RP, Pozdnyakova O, Wong WJ, Lennerz JK, Le LP, Dias-Santagata D, Iafrate AJ, Hobbs GS, Nardi V. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol 2018. PubMed
  • Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer 2018. PubMed
  • DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol 2018; 93:254-261. PubMed
  • Hobbs GS, Hanasoge Somasundara AV, Kleppe M, Litvin R, Arcila M, Ahn J, McKenney AS, Knapp K, Ptashkin R, Weinstein H, Heinemann MH, Francis J, Chanel S, Berman E, Mauro M, Tallman MS, Heaney ML, Levine RL, Rampal RK. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms. Haematologica 2018; 103:e5-e9. PubMed
  • Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv 2018; 1:2032-2040. PubMed
  • Jalbut MM, Brunner AM, Amrein PC, Ballen KK, Hobbs GS, Perry AM, Joseph CP, Fathi AT. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 2017. PubMed
  • Hobbs GS, Rozelle S, Mullally A. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms. Hematol Oncol Clin North Am 2017; 31:613-626. PubMed
  • Perry AM, Brunner AM, Zou T, McGregor KL, Amrein PC, Hobbs GS, Ballen KK, Neuberg DS, Fathi AT. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. Cancer 2017; 123:2561-2569. PubMed